Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions
Overview
Study to determine the safety and efficacy of Mobic® ampoules in the initiation of treatment of painful exacerbations of osteoarthritis, rheumatoid arthritis and other similar painful inflammatory conditions.
Full Title of Study: “Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: March 2005
Interventions
- Drug: Meloxicam
- 7.5 mg or 15 mg
Arms, Groups and Cohorts
- Meloxicam
Clinical Trial Outcome Measures
Primary Measures
- Overall assessment of degree of pain on a 3-point scale
- Time Frame: up to 3 days
Secondary Measures
- Number of patients with adverse events
- Time Frame: up to 3 days
Participating in This Clinical Trial
Inclusion Criteria
- Painful acute exacerbations of inflammatory rheumatism (rheumatoid arthritis and ankylosing spondylitis), painful acute exacerbations of osteoarthritis and other similar conditions requiring acute treatment with an anti-inflammatory drug Exclusion Criteria:
- none
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Boehringer Ingelheim
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.